Clinical Trial Update: Oral EPI-7386 in Patients with Castration-Resistant Prostate Cancer [Phase 1]

View source ↗

Summary

The Phase 1 trial of oral EPI-7386 in patients with castration-resistant prostate cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• EPI-7386

Snippet

Sponsor: ESSA Pharmaceuticals | Conditions: Prostate Cancer | Phase 1 | Status: TERMINATED